Upstream Bio (UPB) Amortizatization of Intangibles (2023 - 2026)
Upstream Bio (UPB) posted quarterly Amortizatization of Intangibles of $754000.0 for Q1 2026, down 56.54% year-over-year from $1.7 million in Q1 2025, and up 154.96% quarter-over-quarter from -$1.4 million in Q4 2025.
Powered by 
Analysis
Upstream Bio (UPB) Amortizatization of Intangibles (2023 - 2026) Analysis & Trends
Upstream Bio's Amortizatization of Intangibles history runs 4 years deep, the most recent figure standing at $754000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 56.54% year-over-year to $754000.0; the TTM figure through Mar 2026 stood at $521000.0 (down 81.17% YoY), while the FY2025 annual figure was $1.5 million, down 9.24% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at $754000.0, up from -$1.4 million in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $1.7 million in Q1 2025, with the low at -$1.4 million in Q4 2025.
- The 4-year median for Amortizatization of Intangibles is $597500.0 (2024), against an average of $415900.0.
- The sharpest annual moves came in 2024 and 2025: Amortizatization of Intangibles slumped 375.0% in 2024, then jumped 178.49% in 2025.
- Upstream Bio's Amortizatization of Intangibles stood at $248000.0 in 2023, then plunged by 375.0% to -$682000.0 in 2024, then sank by 101.17% to -$1.4 million in 2025, then soared by 154.96% to $754000.0 in 2026.
- Business Quant data shows UPB's Amortizatization of Intangibles at $754000.0 in Q1 2026, -$1.4 million in Q4 2025, and $154000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Upstream Bio | 327.95 Mn | 327.95 Mn | -3.29 Mn | 39,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 39,000.00 |
| Mar 31, 2026 | 754,000.00 |
| Dec 31, 2025 | -1.37 Mn |
| Sep 30, 2025 | 154,000.00 |
| Jun 30, 2025 | 985,000.00 |
| Mar 31, 2025 | 1.74 Mn |
| Dec 31, 2024 | -682,000.00 |
| Sep 30, 2024 | 572,000.00 |
| Jun 30, 2024 | 1.14 Mn |
| Mar 31, 2024 | 623,000.00 |
| Dec 31, 2023 | 248,000.00 |